Within this study, 3 sets of the discriminating carrier-protein
bound fragments differentiated samples from patients with ovarian cancer and from apparently healthy controls with sensitivities and specificities of up to 93% and 97%, respectively.
Thus, the rate of formation of the biomarker-carrier-protein complex (BC) is proportional to the product of the biomarker concentration [B] and the carrier-protein concentration [C], with a constant of proportionality [k.sub.f].
The vast excess of carrier protein means that only a tiny proportion of its total concentration will be consumed in the reaction with the biomarker, so that the free carrier-protein concentration [C] may be considered a constant.
The current study brings together a suite of methods and technologies, including novel sample preparation based on carrier-protein
capture and enrichment of biomarkers (17), high-resolution mass spectrometric detection, and bioinformatics analysis that adds statistical and procedural robustness to biomarker discovery from blood, and a unique cohort of well-characterized persons with and without Alzheimer disease (AD).